Core Viewpoint - China Zhongfu (01763) anticipates a decline in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, primarily due to decreased earnings from its nuclear medical equipment division and tax-related expenses from a subsidiary [1] Financial Performance - Revenue is expected to be approximately RMB 6.979 billion to RMB 7.206 billion, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around RMB 611 million to RMB 655 million, reflecting a year-on-year decline of approximately 25% to 30% [1] - Profit attributable to equity shareholders is estimated to be between RMB 302 million and RMB 322 million, indicating a year-on-year reduction of about 20% to 25% [1] Operational Status - The company's operations are currently running normally, despite the anticipated revenue and profit declines [1]
中国同辐(01763)发盈警 预计年度股东应占利润约3.02亿元至3.22亿元 同比减少约20%至25%